Clinical Trial Update: Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating second-line ramucirumab with or without paclitaxel in elderly patients with advanced gastric or gastroesophageal junction cancer. The t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Stomach Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Stomach Cancer, Stomach Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING